<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-09-23T16:12:18Z</responseDate><request verb="GetRecord" identifier="oai:www.repository.cam.ac.uk:1810/317054" metadataPrefix="uketd_dc">https://api.repository.cam.ac.uk/server/oai/request</request><GetRecord><record><header><identifier>oai:www.repository.cam.ac.uk:1810/317054</identifier><datestamp>2024-06-26T14:00:15Z</datestamp><setSpec>com_1810_721</setSpec><setSpec>com_1810_256064</setSpec><setSpec>col_1810_218856</setSpec></header><metadata><uketd_dc:uketddc xmlns:uketd_dc="http://naca.central.cranfield.ac.uk/ethos-oai/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:uketdterms="http://naca.central.cranfield.ac.uk/ethos-oai/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://naca.central.cranfield.ac.uk/ethos-oai/2.0/ http://naca.central.cranfield.ac.uk/ethos-oai/2.0/uketd_dc.xsd">
   <dc:title>The Development of Sulfatase-Cleavable Linkers for Antibody-Drug Conjugates</dc:title>
   <dc:identifier xsi:type="dcterms:DOI">10.17863/CAM.64165</dc:identifier>
   <dc:creator>Bargh, Jonathan</dc:creator>
   <uketdterms:authoridentifier xsi:type="uketdterms:ORCID">0000000330232569</uketdterms:authoridentifier>
   <uketdterms:advisor>Spring, David</uketdterms:advisor>
   <uketdterms:authoridentifier xsi:type="uketdterms:ORCID">0000000173552824</uketdterms:authoridentifier>
   <dcterms:abstract>Antibody-Drug Conjugates (ADCs) are a rapidly growing class of anticancer agents comprising
a small molecule cytotoxin and a monoclonal antibody (mAb). A covalent linker joins the
two therapeutic components, the properties of which are crucial to the success of an ADC.
Although cathepsin-cleavable dipeptides are the most widely used linker motifs, they suffer
from a number of key drawbacks, such as instability in rodent blood and poor aqueous
solubility.
First, this thesis describes the design, synthesis and evaluation of arylsulfates as enzymecleavable
ADC linkers. These arylsulfates were designed to be cleaved by lysosomal sulfatases,
thus revealing a phenolate, primed for 1,6-elimination of a payload within the target
cell (Figure 1A). Initially, a panel of model linkers were synthesised using a neopentyl sulfate
protecting group. Upon analysis under physiological conditions, the linkers were revealed to
be remarkably stable in human and mouse plasma, but cleaved by sulfatases to release
their payload cargo. Each arylsulfate model linker demonstrated a vastly different rate of
sulfatase-mediated hydrolysis, suggesting a variation in their in vitro payload release rates.
Upon these encouraging outcomes, the arylsulfate motifs were elaborated to full linkerpayloads,
incorporating an antibody-attachment handle and a potent cytotoxin. Conjugation
to an antibody was then performed and the resulting ADCs were evaluated in both antigenpositive
and -negative cells. Cell viability data revealed that certain arylsulfate-ADCs were
highly cytotoxic and cell-selective, with a correlation between sulfatase-cleavage rate and
potency. Thus the novel linkers described herein perform similarly to the commonly employed
dipeptides, whilst exhibiting vastly superior plasma stability and aqueous solubility. It
is anticipated that these arylsulfate linkers can be applied to a wide range of potential antibodies
and payloads, especially given their synthetic accessibility.
Second, a sulfated β-galactose-based linker-payload was investigated as an alternative
cleavable group. The linker was designed to be initially cleaved by the lysosomal arylsulfatase
A enzyme, followed by subsequent β-galactosidase hydrolysis and 1,6-elimination of
the payload (Figure 1B). By exploiting this dual-enzymatic cascade, the linker was anticipated
to be extraordinarily hydrophilic and lysosome-selective. Once synthesised, the sulfogalactose
linker-payload was conjugated to an antibody in 100% aqueous media, demonstrating
the solubilising effect of the sulfo-galactose group. The resulting ADC was evaluated
in vitro, revealing similar potency and selectivity to the most toxic arylsulfate-ADC. Thus, the
iv
sulfo-galactose motif is also anticipated to be an effective enzyme-cleavable approach for a
variety of ADC payloads and antibodies. The remarkable aqueous solubility renders the
cleavable motif particularly suited to highly lipophilic payloads.</dcterms:abstract>
   <uketdterms:institution>University of Cambridge</uketdterms:institution>
   <dcterms:issued>2020-10-31</dcterms:issued>
   <dc:type>Thesis</dc:type>
   <uketdterms:qualificationlevel>Doctoral</uketdterms:qualificationlevel>
   <uketdterms:qualificationname>Doctor of Philosophy (PhD)</uketdterms:qualificationname>
   <dc:language>eng</dc:language>
   <uketdterms:sponsor>EPSRC/GSK iCase Award</uketdterms:sponsor>
   <dcterms:isReferencedBy xsi:type="dcterms:URI">https://www.repository.cam.ac.uk/handle/1810/317054</dcterms:isReferencedBy>
   <dc:identifier xsi:type="dcterms:URI">https://apollo8-f-pro.lib.cam.ac.uk/bitstreams/e8d99447-b6d6-4b1f-92ef-3ccdbb1b08c9/download</dc:identifier>
   <uketdterms:checksum xsi:type="uketdterms:MD5">5235841d863c3d7d84c3948f7af05001</uketdterms:checksum>
   <dcterms:license>https://apollo8-f-pro.lib.cam.ac.uk/bitstreams/73cd114a-a677-4057-a784-df627f9d2dfb/download</dcterms:license>
   <uketdterms:checksum xsi:type="uketdterms:MD5">353adac0d1ebdfd65ab16480263c3c87</uketdterms:checksum>
   <dc:rights>https://www.rioxx.net/licenses/all-rights-reserved/</dc:rights>
   <dc:subject>antibody</dc:subject>
   <dc:subject>conjugate</dc:subject>
   <dc:subject>sulfatase</dc:subject>
   <dc:subject>arylsulfate</dc:subject>
   <dc:subject>cleavable</dc:subject>
</uketd_dc:uketddc>
</metadata></record></GetRecord></OAI-PMH>